source
- Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 pushSobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
- Aspo Oyj announces upcoming leadership changes scheduled for August 10, 2026Aspo Oyj, a Finnish specialty chemicals company, issued a brief notice indicating that it will implement leadership transactions. The announcement specifies that the changes will take effect on Au…